Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
21. |
ECCT/25/02/05 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Irene Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute, Kisumu County Referral Hospital (Kisumu county) |
07-03-2025 |
View |
22. |
ECCT/25/02/07 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI-RCTP (Kisumu county) |
13-03-2025 |
View |
23. |
ECCT/25/02/06 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya 1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
06-03-2025 |
View |
24. |
ECCT/25/02/08 | Clearance of High-Risk HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Valentine Chepkorir Sing’oei Site(s) in Kenya 1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) |
06-03-2025 |
View |
25. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
07-07-2017 |
View |
26. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
08-07-2019 |
View |
27. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
08-09-2020 |
View |
28. |
ECCT/13/07/01 | HIVCORE004/N004 A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi. |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Site(s) in Kenya KAVI-KANGEMI RESEARCH SITE |
19-06-2013 |
View |
29. |
ECCT/25/12/03 | ITU512 Study - Site 6002 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Doreen Terry Karimi Mutua Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
30. |
ECCT/25/12/02 | ITU512 Study - Site 6003 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |